MIRA Pharmaceuticals, Inc.
Sağlık
NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.
$0.65
Price (1 Year)
Participation Finance Screening Ratios
Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.
About the Company
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial.
WebsiteAnalysis (Turkish): MIRA Hissesi Caiz mi, Helal mi? MIRA Pharmaceuticals, Inc. Katılım Analizi